Anixa Biosciences (ANIX) to Release Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Monday, January 12th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09).

Anixa Biosciences Stock Down 1.4%

Shares of NASDAQ:ANIX opened at $2.85 on Friday. The firm has a fifty day simple moving average of $3.05 and a two-hundred day simple moving average of $3.55. Anixa Biosciences has a 52 week low of $2.33 and a 52 week high of $5.46. The stock has a market capitalization of $95.13 million, a P/E ratio of -8.14 and a beta of 0.48.

Analyst Ratings Changes

A number of brokerages recently commented on ANIX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a report on Monday, December 29th. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Zacks Research downgraded Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, February 4th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Anixa Biosciences presently has a consensus rating of “Hold” and an average target price of $9.00.

Insider Activity at Anixa Biosciences

In other news, Director Arnold M. Baskies purchased 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 28th. The shares were bought at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the acquisition, the director owned 135,000 shares of the company’s stock, valued at approximately $410,400. This trade represents a 8.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 26.40% of the company’s stock.

Institutional Trading of Anixa Biosciences

Several institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC purchased a new position in shares of Anixa Biosciences during the second quarter valued at approximately $33,000. Cetera Investment Advisers bought a new stake in shares of Anixa Biosciences during the 4th quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. purchased a new position in Anixa Biosciences during the 2nd quarter valued at $37,000. Finally, Millennium Management LLC purchased a new position in Anixa Biosciences during the 4th quarter valued at $38,000. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.